Skip to main content

Table 1 Clinical characteristics of the study cohort

From: Association of thrombocytopenia and infection in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention

Variables

Overall (n = 1401)

Patients with thrombocytopenia (n = 186)

Patients without thrombocytopenia (n = 1215)

p value

Platelet counts (× 109/L)

214.47 ± 64.55

125.81 ± 23.01

228.04 ± 57.76

< 0.001

Age (years)

61.77 ± 12.37

65.99 ± 11.06

61.13 ± 12.43

< 0.001

Male, n (%)

1158 (82.7%)

157 (84.4%)

1001 (82.4%)

0.498

Female, n (%)

243 (17.3%)

29 (15.6%)

214 (17.6%)

 

SBP (mmHg)

122.00 ± 21.64

118.70 ± 21.82

122.50 ± 21.58

0.026

DBP (mmHg)

73.48 ± 12.76

71.63 ± 11.26

73.77 ± 12.96

0.034

Heart rate (bpm)

80.71 ± 16.54

80.78 ± 18.98

80.70 ± 16.14

0.954

Killip classification

1.42 ± 0.77

1.48 ± 0.88

1.41 ± 0.75

0.236

Hypertension, n (%)

724 (51.7%)

97 (52.2%)

627 (51.6%)

0.890

Diabetes, n (%)

367 (26.2%)

54 (29.0%)

313 (25.8%)

0.345

Hyperlipemia, n (%)

145 (10.3%)

14 (7.5%)

131 (10.8%)

0.175

Smoke, n (%)

622 (44.4%)

83 (44.6%)

549 (44.4%)

0.947

COPD, n (%)

34 (2.4%)

6 (3.2%)

28 (2.3%)

0.447

Prior MI, n (%)

72 (5.1%)

16 (8.6%)

56 (4.6%)

0.022

Prior stroke, n (%)

96 (6.9%)

19 (10.2%)

77 (6.3%)

0.051

Bleeding, n (%)

221 (15.8%)

46 (24.7%)

175 (14.4%)

< 0.001

Atrial fibrillation, n (%)

44 (3.1%)

76 (3.8%)

37 (3.0%)

0.601

CABG, n (%)

3 (0.2%)

0 (0.0%)

3 (0.2%)

0.498

Prior PCI, n (%)

140 (10.0%)

16 (8.6%)

124 (10.2%)

0.497

Laboratory characteristics

    

 White blood cell (× 109/L)

11.82 ± 3.83

10.93 ± 3.52

11.95 ± 3.86

< 0.001

 Serum creatinine (μmol/L)

103.78 ± 74.70

124.43 ± 104.83

100.61 ± 68.44

< 0.001

 Triglycerides (mmol/L)

1.57 ± 1.20

1.35 ± 1.55

1.60 ± 1.14

0.010

 Total cholesterol (mmol/L)

4.83 ± 1.19

4.33 ± 1.06

4.91 ± 1.19

< 0.001

 LDL-C (mmol/L)

3.07 ± 1.01

2.65 ± 0.86

3.14 ± 1.02

< 0.001

 HbA1c (%)

6.70 ± 1.73

6.85 ± 1.70

6.68 ± 1.74

0.271

 Serum albumin (g/L)

33.26 ± 4.29

32.41 ± 4.11

33.39 ± 4.31

0.004

 Hemoglobin (g/L)

136.24 ± 18.31

132.03 ± 19.59

136.88 ± 18.03

< 0.001

 LVEF (%)

52.00 ± 11.71

50.79 ± 12.24

52.19 ± 11.61

0.130

Medication during hospital stay

    

 Statins, n (%)

1384 (98.8%)

178 (95.7%)

1206 (99.3%)

< 0.001

 Aspirin, n (%)

1370 (97.8%)

181 (97.3%)

1189 (97.9%)

0.636

 Clopidogrel, n (%)

1384 (98.8%)

178 (95.7%)

1206 (99.3%)

0.593

 CCB, n (%)

149 (10.6%)

27 (14.5%)

122 (10.0%)

0.065

 Olmesartan, n (%)

225 (16.1%)

30 (16.1%)

195 (16.0%)

0.978

 New antibiotic use, n (%)

240 (17.1%)

53 (28.5%)

187 (15.4%)

< 0.001

Procedural characteristics

    

 Radial access, n (%)

1191 (85.0%)

155 (83.3%)

1036 (85.3%)

0.491

 Femoral assess, n (%)

210 (15.0%)

31 (16.7%)

179 (14.7%)

 

 Contrast volume, (mL)

114.01 ± 42.81

117.86 ± 42.40

113.41 ± 42.86

0.213

 Number of stents, (n)

1.30 ± 0.82

1.38 ± 0.88

1.28 ± 0.81

0.153

 Total length of stent, (mm)

32.51 ± 22.38

34.67 ± 23.04

32.28 ± 22.27

0.158

  1. Data are presented as mean ± SD or number (percentage)
  2. SBP systolic blood pressure, DBP diastolic blood pressure, COPD chronic obstructive pulmonary disease, MI myocardial infarction, TC total cholesterol, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, LDL-C low-density lipoprotein cholesterol, LVEF left ventricular ejection fraction, CCB calcium channel blockers
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us